Associate Professor
Case Comprehensive Cancer Center
Ankit Mangla, MD, is a medical oncologist at University Hospitals Seidman Cancer Center with expertise in treating patients with melanoma and rare tumors such as Merkel cell cancer and soft tissue sarcoma. His specific areas of interest are the use of neoadjuvant immunotherapy in patients diagnosed with melanoma and drug development. He also serves as the Co-Director (Medical Oncology) of the sarcoma and melanoma disease teams.
Dr. Mangla earned his medical degree from Armed Forces Medical College in India and served in the Army Medical Corps of the Indian Army for five years. He completed a residency in internal medicine followed by a fellowship in hematology and oncology at the John H. Stroger Jr. Hospital of Cook County in Chicago, Illinois. Dr. Mangla joined University Hospitals/Case Western Reserve University in 2018. As a clinical investigator at UH Seidman Cancer Center, Dr. Mangla serves as a principal investigator for several phase I, II and III clinical trials. Dr. Mangla has authored several research papers in high-impact journals such as the New England Journal of Medicine, Journal of Clinical Oncology and JAMA Oncology. He was one of the investigators on the SWOG-1801 study studying the effects of neoadjuvant pembrolizumab in patients with melanoma. Conducted through the Southwest Oncology Group, this trial defined a new standard of care for patients with clinical stage 3 melanoma. Results of the trial were published in the New England Journal of Medicine. Dr. Mangla participates in several oncology consortiums and actively contributes to drug development discussions.
Dr. Mangla has been an invited lecturer, expert panelist and poster presenter at numerous conferences. He is a member of professional societies including the American Society of Clinical Oncology, Society for Immunotherapy of Cancer, Connective Tissue Oncology Society, and International Cardiology Oncology Society